Go back

Chemotherapy Induced Peripheral Neuropathy (CIPN): Neurotoxicity and Chemotherapy - An Oncology Perspective

16m 28s

Chemotherapy Induced Peripheral Neuropathy (CIPN): Neurotoxicity and Chemotherapy - An Oncology Perspective

Chemotherapy-induced peripheral neuropathy (CIPN) remains a major challenge in oncology, impacting both patients’ quality of life and treatment adherence. Despite increased awareness, it is still under-recognized in routine clinical practice due to time constraints and systemic prioritization of cancer-specific outcomes over toxicities. The condition arises from diverse mechanisms and varies widely between patients, making prediction and prevention difficult. Current research highlights the potential of non-pharmacological strategies—such as physical therapy, exercise, and yoga—as effective and accessible interventions. Patient-reported outcomes and emerging digital biomarkers offer promising tools for early detection and personalized monitoring. However, broader implementation requires systemic changes, including improved workflows and integration of patient voices. A critical solution lies in cross-disciplinary collaboration, bringing together oncologists, neurologists, rehabilitation experts, and researchers through team science approaches. Funding and clinical initiatives are increasingly supporting such models, especially in symptom-focused research. As new chemotherapies like antibody-drug conjugates emerge, a coordinated, patient-centered strategy is essential to improve detection, management, and long-term outcomes for patients experiencing CIPN.

Transcription

2200 Words, 13323 Characters

English
Welcome to the peripheral nerve podcast, the official podcast of the peripheral nerve society, exploring topics and peripheral nerve disorders, awareness, education, and advocacy. We are your host, Professor Susanna Park from the University of Sydney, Australia, and Dr. Paul Alberti from University of Milano Bicocca, Italy. We are delighted to bring you another episode in the peripheral nerve podcast series, Understanding chemotherapy induced peripheral neuropathy. In this episode, we are excited to discuss CIPN on the perspective of her medical oncologist. We are honored to welcome Professor Mariam Lustberg. Professor Lustberg is a leader in advancing patient-centered cancer care. She is the chief of breast medical oncology at Yale Cancer Center and the director of the Center for breast cancer at Smiler Cancer Hospital. Professor Lustberg's clinical and research work has a strong focus on improving long-term outcomes for people with cancer, including addressing toxicity such as chemotherapy induced peripheral neuropathy. They work as a substantial impact across clinical research and advocacy settings. Improving cancer outcomes and quality of life, in partnership with international organizations such as the multinational association for supporting care in cancer. Today, we will discuss our CIPN affects cancer care and what work needs to be done to address this challenge and improve patient outcome. Welcome, Professor Lustberg. It's so wonderful to have you here with us today. Thank you both and thank you for that very nice introduction. I'm very happy to be here with you both. I could start with a question, "A significant do you think CIPN is in oncology practice today?" And how it increased awareness change its role in routine care. I think chemo induced neuropathy continues to impact a large proportion of our patients, classic agents that I'm sure we'll talk about, are still being routinely used in clinical practice and many of our patients continue to suffer from both acute manifestations of neuropathy during treatment and many continue to may have chronic sequelae that can linger. So it is absolutely a quality of life issue and in addition, it can actually impact our ability to deliver effective agents for their cancer. So when they have very significant neuropathy, it can lead to dose interruptions and dose reductions and sometimes even discontinuation of therapy. So as I think about the importance of neuropathy, absolutely quality of life is important, but equally important and this is obviously also meaningful to our patients is their disease outcomes. And neuropathy has an impact on both. Thank you so much. Do you think that there's been increased awareness over CIPN over time, or it's always been a significant issue? Overall, we have been trying as a community clinicians and oncology to give greater attention to all kinds of supportive care issues and then quality of life issues, I think throughout the world due to wonderful efforts of the patient advocate community. I think we are a bit more aware that patients need as much information about the potential toxicities of the cancer treatments they're embarking on. So I do think there is greater awareness, but in many ways when you take that average oncology clinic day to day, I do still worry that even though we have a number of tools that I'm sure we'll talk about, just in a standard, busy oncology clinic, I think it's much the same where we're all rushing and perhaps not paying as much attention as we should. Thank you, and in light of this, we would be very grateful if you could give us your insight on why despite its clinical relevance, CIPN is still challenging to be predicted, prevent it and treated. Yeah, it's fascinating to start out with, I think, chemo-induced neuropathy and both of you know, has multiple different mechanisms of injury due to the agents that is viewed. So, you know, we love it all together, but each of these agents can have its own very precise biological mechanism of injury, and so in many ways I think mechanistic studies, although I'm very grateful to many laboratory scientists who have devoted their laboratories to studying this, still I think there is heterogeneity in mechanisms as well as there are many things we still don't fully understand about the mechanism of injury. So that's one piece of it that makes it challenging. The second is the host, the patient herself could have great heterogeneity in terms of the response to these agents, how toxic they can be to the host so that induces additional variability and we all share a colleague who has spent a lot of time studying the pharmacokinetics and pharmacogenomics of neuropathy, but there's still so much we don't know and due to inability to clearly validate some of these findings, they have not made it into root and practice. And then third, I think for both patients and oncologists, from where we start from the focus often is on the cancer treatment first, and some of these other toxicities and quality of life issues, at least initially becomes a kindery, we are investing tremendous amount of resources to developing new therapeutics and this is obviously a good thing and understandable. But part for part, I think the investment and resources devoted to supportive care research for things like neuropathy are much less financial incentive in some ways. So I think it's a very multifaceted problem and for many patients until they experience neuropathy, they may not fully understand how devastating it can be. So this has also hindered large groups of studies that have focused on prevention, where patients kind of it's been actually very challenging to enroll patients in prevention studies because to devote the resources and time as a patient to actually enroll in a prevention study, has been quite challenging and no fault to their patients, they're busy with their treatment and their lives and until it happens to you, it's a theoretical problem. And what we hear on the back and is I wish I had known how much this can affect my life. So in response to your excellent question, I think there's multiple factors that have gone into this and now we have newer agents that are also causing neuropathy. We have a new set of drugs known as antibody, drug conjugates that are contributing to neuropathy and completely new mechanism so huge problem, but I think if we can come together from multiple disciplines and really tackle it from that multi-deep perspective, that's our best chance for success. Thank you for this detailed overview and given that unfortunately we do not have a pharmacological treatment so far, could you give us your opinion about the role of rehabilitation strategies, physical therapy and lifestyle intervention in managing CIP and symptoms in clinical practice? Yes, so important, the non-pharmacological approaches. We actually have the most promising data for, so oncologic rehab, physical therapy with a focus on balance training and gate training, making sure that patients are safe and they're simple exercises that can be done to improve balance, these are super important. In addition, a physical therapist can work with a patient experiencing neuropathy and develop a tailored exercise program where we do have growing body of data that exercise can be beneficial for patients with symptomatic neuropathy. Our oncology rehab colleagues are not utilized enough and I think this is quite an important part of helping our patients who have experience neuropathy and then I think there is also a growing attention to what we call prehabilitation so taking patients before the problem has happened and really focusing on ways to lower the chance of these problems happening so a little bit less data for that approach but this is something that I think is important in many facets of cancer care so I think from that risk reduction prevention approach, also there is a growing body of literature to support that but certainly we do have good data for patients who are already symptomatic oncology rehab can be helpful in a In addition, there is a number of other non-pharmacological studies that are, as you know, in progress, including the Phase 3 study currently ongoing for yoga based on promising Phase 2 data. And there is an ongoing Phase 3 study with electroacupuncture versus sham acupuncture and standard care. And so both studies are being done based on promising earlier Phase studies coming back to just the promise of the non-pharmacological approaches where we have many more failed studies with the pharmacological approaches. I think that there is great excitement for these non-pharmacological approaches and any type of movements. We had exercise, yoga, my lab focuses on dance training, so all of these are showing comments in earlier Phase studies. I need to be confirmed in larger studies. Thank you so much. Are there any emerging technologies that you believe could meaningfully change how we assess and manage CIPN in the next decade? I think the growing use of patient-reported outcomes. We have known for decades that patients reporting of toxicity, whether it be neuropathy or other toxicities, is one of the best ways of capturing the patient experience where the clinician reporting can often under-report symptoms. So we have known for quite some time that patient-reported outcomes are quite important in categorizing the experience of neuropathy as well as other toxicities. But we have not, depending on what part of the world you are working in, and not all clinics have to have standardly implemented, good workflows for routine use of patient-reported outcomes outside of clinical trials. I do see that changing. I think this is going to become much more mainstream, so I think being able to streamline our PRR reporting will be tremendously helpful. I also see the emergence of additional biomarkers from body sensors being able to capture balance and gates and heart rate variability. There are so many different emerging digital biomarkers where I think for very little effort as technology improves, we could have a body of data that tells us much more precisely how our patient is doing both in terms of neuropathy but as well as other toxicities. I do see that as an exciting development in the coming years, and would potentially allow us to intervene sooner before toxicities get more serious, it may allow us to direct these patients toward earlier clinical trials for symptom toxicities. Those are one of the things I'm very excited about. The base biomarkers are also actively being studied, including neurofilament-light chains and others. I think they need some time before they are fully validated and able to be used in routine use, but I do believe that there's not going to be one single biomarker for neuropathy, but what we call this type of multiplexing of different biomarkers coming together, and I think we'll finally have the technological advances to be able to gather all these data together, synthesize them, and be able to eventually feed it back to the clinician and the patient so that true shared decision-making can be made. Thank you so much for these detailed overview. To wrap up our session, we have a question that actually is connected to something you mentioned already about collaboration, which is your take on how we can foster effective cross-disciplinary collaboration among oncologists, neurologists, and other healthcare professionals involved in the care of patients affected by CI/PN. I think it's the premise of team science for multi-faceted complex problems, such as chemotherapy and dysnorectomy. These work silos are not effective, so similar to the work that you have done bringing these diverse teams together, I think that's the answer, is it always easy, no? I think when neurologists and basic researchers and oncologists are actually at a virtual or real table discussing these problems, coming up with the most pressing, clinical, and translational questions, I think that's the most exciting, this is what our patients need, and I think funding agencies are beginning to value even more the promise of team science, and I think that's going to also further advance this, where I just saw a solicitation for a symptom science grant, and it's specifically said that they wanted a PhD and a clinician to work together, so I see more of that coming, and I think that will help further strain the idea that this type of multi-D team science is truly the way to go. I definitely agree with you, let's hope that would be a path in the future. Thank you, Professor Lusper, for sharing your insights. You can find relevant papers in the show notes and visit www.pns.com for more information about the free-from-net society, thank you for listening, see you next month. The primary purpose of the peripheral nerve podcast is to meet the educational needs of its listeners and address practice gaps by providing practice oriented and scientifically based education that will maintain an advanced competence and performance in the peripheral nerve field. A diversity of opinions exists in the medical field, and the views of the podcast faculty do not represent those of the peripheral nerve society, or constitute an endorsement by the peripheral nerve society.

Podcast Summary

Key Points:

  1. Chemotherapy-induced peripheral neuropathy (CIPN) remains a significant and widespread issue in oncology, affecting both quality of life and cancer treatment efficacy.
  2. While awareness of CIPN has improved due to patient advocacy and supportive care efforts, routine clinical practice often still underprioritizes its monitoring and management.
  3. CIPN is challenging to predict, prevent, and treat due to diverse mechanisms of injury, patient variability, and limited understanding of pharmacogenomic influences.
  4. Non-pharmacological interventions such as physical therapy, balance training, exercise, yoga, and electroacupuncture show promising evidence and should be integrated into clinical practice.
  5. Patient-reported outcomes and digital biomarkers (e.g., balance, heart rate variability) are emerging as powerful tools for early detection and personalized management of CIPN.
  6. Cross-disciplinary collaboration between oncologists, neurologists, and rehabilitation specialists is essential for advancing research and improving patient outcomes.
  7. Newer treatments like antibody-drug conjugates introduce novel neuropathy risks, highlighting the need for updated clinical strategies and research focus.
  8. A multi-faceted, team-science approach combining clinical, research, and patient-centered perspectives is critical to overcoming current limitations in CIPN care.

Summary:

Chemotherapy-induced peripheral neuropathy (CIPN) remains a major challenge in oncology, impacting both patients’ quality of life and treatment adherence. Despite increased awareness, it is still under-recognized in routine clinical practice due to time constraints and systemic prioritization of cancer-specific outcomes over toxicities. The condition arises from diverse mechanisms and varies widely between patients, making prediction and prevention difficult.

Current research highlights the potential of non-pharmacological strategies—such as physical therapy, exercise, and yoga—as effective and accessible interventions. Patient-reported outcomes and emerging digital biomarkers offer promising tools for early detection and personalized monitoring. However, broader implementation requires systemic changes, including improved workflows and integration of patient voices.

A critical solution lies in cross-disciplinary collaboration, bringing together oncologists, neurologists, rehabilitation experts, and researchers through team science approaches. Funding and clinical initiatives are increasingly supporting such models, especially in symptom-focused research. As new chemotherapies like antibody-drug conjugates emerge, a coordinated, patient-centered strategy is essential to improve detection, management, and long-term outcomes for patients experiencing CIPN.

FAQs

CIPN is a common side effect of chemotherapy that affects the peripheral nerves, causing pain, numbness, and weakness. It is significant because it impacts patients' quality of life and can lead to dose reductions or treatment discontinuation, affecting cancer outcomes.

Yes, awareness has increased due to patient advocacy and better education on treatment toxicities. However, in busy clinical settings, neuropathy is still often overlooked due to time constraints and routine focus on cancer treatment.

CIPN is challenging due to diverse mechanisms of nerve injury, patient variability in sensitivity, lack of validated pharmacogenomic data, and limited investment in supportive care research compared to cancer therapies.

Physical therapy, balance training, exercise, yoga, and electroacupuncture show promise in managing symptoms. These approaches are increasingly supported by clinical evidence and are recommended as part of comprehensive care.

Yes, patient-reported outcomes and digital biomarkers—like balance and heart rate variability—are emerging tools. Wearable sensors and biomarkers such as neurofilament-light chains may enable earlier detection and personalized interventions.

Collaboration between oncologists, neurologists, and rehabilitation specialists is essential. Shared decision-making and team science approaches lead to better patient outcomes by combining clinical, research, and patient perspectives.

Chat with AI

Loading...

Pro features

Go deeper with this episode

Unlock creator-grade tools that turn any transcript into show notes and subtitle files.